# A Prospective Study to Evaluate Revita DMR Post Market Pilot Clinical Follow-Up Registry in Patient With Type 2 Diabetes

> **NCT06256497** · — · SUSPENDED · sponsor: **Fractyl Health Inc.** · enrollment: 100 (estimated)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DEVICE:** Duodenal Mucosal Resurfacing (DMR)

## Key facts

- **NCT ID:** NCT06256497
- **Lead sponsor:** Fractyl Health Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** SUSPENDED
- **Start date:** 2023-06-27
- **Primary completion:** 2028-07-01
- **Final completion:** 2028-12-01
- **Target enrollment:** 100 (ESTIMATED)
- **Why stopped:** The company paused enrollment due to a strategic decision to pause commercialization in the EU and specifically Germany. The company will follow currently enrolled subjects per protocol.
- **Last updated:** 2025-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06256497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06256497, "A Prospective Study to Evaluate Revita DMR Post Market Pilot Clinical Follow-Up Registry in Patient With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06256497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*